Literature DB >> 3147477

Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.

J P Desager1, R Hulhoven, C Harvengt, P Hermann, P Guillet, J F Thiercelin.   

Abstract

The combined use of a hypnotic and a neuroleptic is a rather frequent situation, encountered especially in the psychiatric sphere. We therefore tested zolpidem and chlorpromazine in six healthy subjects by using a double-blind latin square design. All of them received single doses of 20 mg zolpidem (ZOL), 50 mg chlorpromazine (CPZ) and the combination of ZOL + CPZ. The medication was given as a single dose in the morning and each treatment being separated by a 1-week interval. Zolpidem produced moderate to severe sedation varying according to the subjects. Psychometric performances (manual dexterity, Stroop test), alertness and psychomotricity (visual analogue scales) were reduced up to 3 h after drug intake. Chlorpromazine alone did not have much effect. Combined administration of ZOL and CPZ was rather more effective than ZOL alone. The pharmacokinetics of ZOL or CPZ remained unchanged except for the elimination half-life of CPZ, which increased significantly when administered along with ZOL. No other pharmacodynamic or pharmacokinetic interaction between ZOL and CPZ was evident. The fact that the ZOL and CPZ combination accentuated the pharmacodynamical effects can be explained to result from the summation of each of their own pharmacological effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147477     DOI: 10.1007/bf02431534

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  High-performance liquid chromatographic determination of zolpidem, a new sleep inducer, in biological fluids with fluorimetric detection.

Authors:  P Guinebault; C Dubruc; P Hermann; J P Thénot
Journal:  J Chromatogr       Date:  1986-11-28

2.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.

Authors:  R Gomeni
Journal:  Comput Biol Med       Date:  1984       Impact factor: 4.589

3.  Analysis of chlorpromazine in plasma: effect of specimen storage.

Authors:  R N Gupta; G Bartolucci; G Molnar
Journal:  Clin Chim Acta       Date:  1981-02-05       Impact factor: 3.786

4.  Hypnotic activity of an imidazo-pyridine (zolpidem).

Authors:  A N Nicholson; P A Pascoe
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

5.  Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats.

Authors:  S Arbilla; H Depoortere; P George; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-09       Impact factor: 3.000

6.  Zolpidem, a novel nonbenzodiazepine hypnotic. II. Effects on cerebellar cyclic GMP levels and cerebral monoamines.

Authors:  B Scatton; Y Claustre; T Dennis; T Nishikawa
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

7.  The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic.

Authors:  D J Sanger; B Zivkovic
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  7 in total
  10 in total

Review 1.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 2.  Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.

Authors:  H D Langtry; P Benfield
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

3.  Zolpidem reduces the blood oxygen level-dependent signal during visual system stimulation.

Authors:  Stephanie C Licata; Steven B Lowen; George H Trksak; Robert R Maclean; Scott E Lukas
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-05-30       Impact factor: 5.067

Review 4.  Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem.

Authors:  G Chouinard; K Lefko-Singh; E Teboul
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 5.  Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications.

Authors:  P Salvà; J Costa
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

Review 6.  Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Authors:  Leah M Hesse; Lisa L von Moltke; David J Greenblatt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 7.  Comparative tolerability of newer agents for insomnia.

Authors:  Gary Zammit
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial.

Authors:  Lawrence A Galitz; Shyamalie Jayawardena; Sandy A Furey
Journal:  Drugs R D       Date:  2015-03

9.  The antioxidant and neuroprotective effects of Zolpidem on acrylamide-induced neurotoxicity using Wistar rat primary neuronal cortical culture.

Authors:  Bahareh Sadat Yousefsani; Nasim Akbarizadeh; Jalal Pourahmad
Journal:  Toxicol Rep       Date:  2020-01-27

10.  A computerized stroop test for the evaluation of psychotropic drugs in healthy participants.

Authors:  Raveendranadh Pilli; Mur Naidu; Usha Rani Pingali; J C Shobha; A Praveen Reddy
Journal:  Indian J Psychol Med       Date:  2013-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.